Venom immunotherapy: safety and tolerability of the build-up phase with depot versus aqueous preparations
Clin Exp Allergy
.
2022 Oct;52(10):1230-1233.
doi: 10.1111/cea.14209.
Epub 2022 Jul 29.
Authors
Valerio Pravettoni
1
,
Marina Mauro
2
,
Federica Rivolta
1
,
Dario Consonni
3
,
Camilla Cappelletti
4
,
Alessandra Chiei Gallo
4
,
Andrea Sangalli
4
,
Maria Beatrice Bilò
5
6
Affiliations
1
UOC General Medicine Immunology and Allergology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
2
U.O.S. Allergology, Hospital S. Anna Como ASST Lariana, Como, Italy.
3
Epidemiology Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
4
Allergy and Clinical Immunology Residency, University of Milan, Italy.
5
DISCLIMO (Department of Clinical and Molecular Sciences), Università Politecnica delle Marche, Ancona, Italy.
6
Allergy Unit, Department of Internal Medicine, University Hospital Ospedali Riuniti, Ancona, Italy.
PMID:
35904013
PMCID:
PMC9796821
DOI:
10.1111/cea.14209
No abstract available
Publication types
Letter
Research Support, Non-U.S. Gov't
MeSH terms
Bee Venoms*
Desensitization, Immunologic* / adverse effects
Humans
Immunotherapy
Wasp Venoms
Substances
Bee Venoms
Wasp Venoms